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Summary. Currently, there are few data on the effect of cardiovascular drugs on the immune 
status of patients with heart failure (HF). This paper provides information on the impact of  
ß-adrenergic blocking agent (BAB), angiotensin-converting enzyme inhibitors (ACEI) on the 
maintenance of markers of immune inflammation in the blood, as well as on inhibition of 
synthesis of tumor necrosis factor-α (TNF-α) and on blocking of interaction between TNF-α and 
membrane receptors. 
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Аннотация. В настоящее время имеется немного данных о влиянии сердечно-сосудистых 
препаратов на иммунный статус больных с сердечной недостаточностью (ХСН). В данной статье 
освещены аспекты влияния ß-адреноблокаторов (БАБ),  ингибиторов ангиотензинпревращающего 
фермента(ИАПФ) на содержание в крови маркеров иммунного воспаления, а так же на 
ингибирование синтеза фактора некроза опухоли-α (ФНО-α) и блокирующих взаимодействие  
ФНО-α с мембранными рецепторами.  
Ключевые слова. Иммунное воспаление, хроническая сердечная недостаточность, ишемическая 
болезнь сердца, фактор некроз опухоли-α, ß-адреноблокаторы, ингибиторы 
ангиотензинпревращающего фермента. 
 
A congestive chronic heart failure is a clinical 
syndrome characterized by malaise, shortness of 
breath, swelling and other symptoms, primarily 
associated with the impairment of tissue perfusion, 
resulting from many cardiovascular diseases of both 
inflammatory (myocarditis, dilated cardiomyopathy), 
and non-inflammatory (coronary artery disease, 
arterial hypertension, hypertrophic and restrictive 
cardiomyopathy, etc.) nature [9.21]. Until recently, 
the pathophysiological processes that lead to the 
development of heart failure were considered 
primarily from the perspective of neurohormonal 
hypothesis based on concepts of overexpression of 
neurohormones initiating remodeling and progression 
of dysfunction of the left ventricle (LV) and 
desensitization of the cardiomyocyte (CMC) b1-
receptor-G-protein complex, which results in 
weakness of myocardial contractility [15].  
The role in the congestive chronic heart failure 
progression is assigned to the neurohormonal 
activation, and the sense of sympathoadrenal nervous 
system (SAS) becomes more and more clear. The 
literature presents data on changes in the level of 
catecholamines, renin, angiotensin and aldosterone at 
various stages of ischemic CHF progression, starting 
from the occurrence of acute myocardial infarction 
(AMI) and until the end-stage of heart failure [8, 19, 
20]. It is known that patients with CHF have 
significantly higher SAS values with the increase in 
TNF-α level in plasma than the patients with CHF 
who have normal levels of TNF-α [6]. It was found 
that the levels of adrenaline, noradrenaline, 
aldosterone, and cortisol was higher in patients with 
cardiac cachexia as compared with patients without 
cachexia [17]. However, there are another data, for 
example, G. Torre-Amione et al., using a SOLVD 
database, found no intensity correlation between the 
inflammatory response and neurohormonal activity 
of plasma in patients with chronic heart failure [14].  
A starting moment in the mechanism of 
neurohormonal activation is the reduction in cardiac 
output at LV dysfunction, which leads to a decrease 
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in blood pressure (BP), stimulating in turn the 
baroreceptors (blood high-pressure receptors and 
cardiopulmonary low-pressure receptors). As a result, 
the flow of impulses into the central nervous system 
increases, causing the rise in both the SAS and renin-
angiotensin-aldosterone system (RAAS) activity, 
which is accompanied by increased cardiac output 
(positive inotropic effect of catecholamines) and 
improved blood supply to vital organs and skeletal 
muscles (the effect of vasoconstriction). 
Currently, there are already-formed ideas about 
the negative role of SAS chronic hyperactivation in 
patients with CHF due to its main mechanism of 
action via stimulation of catecholamine beta-receptors 
(primarily noradrenaline) and activation of adenylate-
cyclase mechanism that increases the content of cyclic 
AMP (cAMP). This mechanism enhances calcium 
entering into the cell and its mobilization from 
sarcoplasmic reticulum, which is accompanied by 
increased contractility. Chronic activation leads to a 
gradual overflow of myocardial cells with calcium, 
their contracture, a impairment of electrical stability 
and membrane integrity, and the CMC necrosis, which 
is manifested by toxic effects of catecholamines on the 
myocardium. Hyperactivity of neurohumoral systems 
stimulates the production of other neurohormones and 
mediators, including some cytokines that have 
proinflammatory action, which predetermines the 
development of pathological changes in the peripheral 
tissues. Furthermore, noradrenaline together with 
angiotensin-II (A-II) stimulate the activation of growth 
factor and increase the synthesis of cytokines, which is 
accompanied by the development of hypoxic stress, 
the stimulating development of myocardial 
hibernation, and eventually increased cell mortality 
caused by apoptosis. It is known that the main effector 
RAAS A-II, in turn, increases the production and 
release of noradrenaline. Thus, the reciprocal 
activation of the RAAS and SAS generates a vicious 
circle. Elevated concentrations of catecholamines also 
gives indirect effect through RAAS, in the renal 
juxtaglomerular apparatus where the ß-adrenergic 
receptors are located, the stimulation of which 
enhances the release of renin. Finally, noradrenaline 
increases the pacemaker activity of cells of the cardiac 
conduction system by increasing the heart rate (HR), 
myocardial oxygen demand, and the risk of 
arrhythmias [5]. 
It is now apparent that, in addition to the classic 
neurohormones, the overexpression of another class 
of biologically active substances – cytokines – can 
make a significant contribution to the development 
and progression of chronic heart failure. Indeed, 
along with circulatory disorders observed in patients 
with CHF, there are clinical symptoms observed, 
typical of chronic inflammatory diseases and 
malignancies. These primarily include cardiac cachexia 
syndrome, which is manifested by progressive weight 
loss, anorexia and a number of biochemical 
abnormalities typical of malnutrition (anemia, 
hypoalbuminemia, leukopenia, hypocholesteremia) and 
inflammation (increase in erythrocyte sedimentation 
rate, fibrinogen, and acute-phase proteins). Materials 
relating to the participation of pro-inflammatory 
cytokines in the development of heart failure, may be of 
practical importance for the development of new 
approaches to the treatment of this pathology and 
decryption of mechanisms of action of already applied 
pharmacological agents. Currently, there are few data 
on the effect of cardiovascular drugs on the immune-
inflammatory status of patients with chronic heart 
failure. Features of the pathogenesis of this state, 
including cytokinin aggression, necessitate the 
development of new approaches to its pharmacological 
correction with the use of modulators of the cytokine, 
and neurohormonal systems, as well as investigation of 
the influence of drugs used in standard CHF therapy on 
the level of pro- and anti-inflammatory cytokines [4]. 
A particular importance is attached to TNF-a, 
which at its low concentration plays an important 
physiological role in tissue homeostasis regulation, 
and at high concentrations has a pathological 
endocrine-similar effect, causing metabolic 
exhaustion, microvascular hypercoagulability, and 
hemodynamic disturbances. As early as in 1985  
J. Parillo et al. found in the sera of patients with 
septic shock a «myocardial depressive substance», 
which was later identified as TNF-a. In 1990 B. 
Levine et al. first discovered the increased levels of 
TNF-a in patients with CHF. TNF-a has the ability to 
increase the catabolism of proteins, but, however, 
along with other cytokines, in particular interleukin-
1b (IL), increases the protein synthesis and causes 
myocardial hypertrophy of CMC. TNF-a and IL-1 are 
synthesized simultaneously, have the ability to induce 
the production of each other, and demonstrate 
numerous general effects. TNF-a is synthesized by 
monocytes, macrophages, and lymphocytes under the 
influence of endotoxins, viruses, and other cytokines.  
TNF-a and TNF-b bind to two high-affinity surface 
cell receptors with molecular weights of 55 kd and  
75 kd, respectively, that are expressed on the 
membranes of many cells (T-lymphocytes, 
macrophages, neutrophils, etc.), which are released 
into body fluids during activation of mononuclear 
cells and involved in the implementation of the 
biological effects of TNF-a. Recent studies have 
shown that TNF-a and IL-1b have the ability to 
disrupt the function of cardiac muscle in patients with 
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burn and septic shocks, myocarditis, graft rejection, 
and chronic heart failure [29]. Along with 
cardiotropic effects, TNF-a is involved in the 
development of cachexia in cancer patients and in 
patients with severe heart failure. According to the 
findings of experimental studies, TNF-a and IL-1b 
inhibit myocardial contractility in vivo when 
administered to intact animals, and in vitro when to 
the models of isolated heart, isolated papillary 
muscles, and in the CMC culture, contributing to LV 
remodeling by breaking and inducing the CMC 
apoptosis. Low concentrations of TNF-a cause rapid, 
reversible, independent of nitric oxide and 
prostaglandins decrease in intracellular calcium 
content.  High concentrations of TNF-a otherwise 
induce a rapid and reversible decrease in the 
contractile ability of CMC, and this effect is canceled 
by inhibitors of nitric oxide synthetase. In the study, 
the administration of TNF-a caused a 15-20% 
reduction in ejection fraction (EF) under the absence 
of the dynamics of blood pressure and heart rate. 
Moreover, continuous infusion of TNF-a induced a 
time-dependent impairment of LV remodeling, 
manifesting itself in increased LV dilatation along 
with the decreased LV thickness, and these changes 
were not fully reversible after discontinuation of 
TNF-a, or during administration of fc-receptors.  
These findings suggest that the impaired LV 
remodeling is associated with TNF-induced 
degradation of the fibrillar collagen matrix. It is 
known that the TNF has the ability to activate the 
expression of matrix metalloproteinases (MMPs), 
which cause the degradation of extracellular matrix 
proteins. It was established that CMC of patients with 
heart failure and sepsis are capable of expression and 
synthesis of TNF-a, while CMC of people without 
heart failure do not have this ability. Thus, TNF-a, 
along with noradrenaline, endothelin, and A-II, is 
involved in the progression of myocardial 
dysfunction and remodeling in patients with chronic 
heart failure [12]. Since TNF-α plays a central role in 
the mechanism of development and progression of 
chronic heart failure, search for drugs is aimed 
mainly at the synthesis of drugs with the ability to 
inhibit the TNF-α synthesis or block the TNF-a 
interaction with membrane receptors. 
Application of ß-blockers in CHF break a 
vicious circle ending with SAS chronic 
hyperactivation, by blocking all the above 
mechanisms of negative impact of the increased 
catecholamine content. Positive effects of ß-blockers 
in patients with chronic heart failure are as follows: a 
reduction in heart rate, ischemia (myocardial 
hypoxia), myocardial hypertrophy, the CMC death 
(by necrosis and apoptosis), dimensions (dilatation) 
of left ventricle, the restoration of ß-receptors 
sensitivity and response to external stimuli, an 
improvement of diastolic relaxation, and reduction in 
CMC electrical instability (arrhythmias). But not all 
ß-blockers can have a beneficial effect on the clinical 
signs and hemodynamic disorders in patients with 
CHF. Summing up the findings obtained in large 
randomized trials like CIBIS, CIBIS-II, MERIT-HF 
and COPERNICUS Q, we can conclude that 
currently there are at least 3 BABs able to 
significantly improve the efficiency of traditional 
therapy. The most promising BABs for long-term use 
in nowadays are four drugs such as bisoprolol, 
bucindolol, carvedilol and metoprolol. 
For example, a 4-week use of carvedilol in CHF 
contributed to significant reduction in the levels of 
proinflammatory cytokines IL-1β, IL-6, a fibrogenic 
cytokine, and a transforming growth factor-β1 in the 
myocardial tissue, and was associated with reduction 
of MMP activity, fewer myocardial collagen and 
increased expression of IL-10. 
The level of proinflammatory IL-6 decreased by 
more than 5 times in the course of therapy with 
carvedilol. Plasma content of γ-interferon has reached 
the control values. Reduction in IL-6 content in the 
course of carvedilol therapy may result not only from 
the hypotensive action of the drug, but also its 
vasoprotective properties [1]. The use of Carvedilol 
for 4-6 weeks in the treatment of CHF due to ischemic 
heart disease combined with type 2 diabetes and the 
ejection fraction >40%, showed in comparison with 
metoprolol a significant decrease in aldosterone level 
by 20%, and brain natriuretic peptide – by 30 % [16].  
The influence of 24-week pharmacotherapy with 
Bisoprolol in patients with chronic heart failure with 
the activation of cytokines led to the decrease in  
TNF-a concentration in blood plasma by 87% [7, 10]. 
A mandatory group of drugs used in the 
treatment of chronic heart failure that improves 
survival of patients is ACE inhibitors. The positive 
effects of enalapril ACE inhibitors on further life of 
patients with chronic heart was demonstrated for the 
first time during the CONSENSUS in 1987. It was 
found that the mortality in the group treated with 
enalapril is significantly lower than in the control 
group. These results were later confirmed in 
subsequent major randomized trials in relation to 
other ACE inhibitor drugs [12]. 
All positive pharmacological effects of ACE 
inhibitors observed in heart failure can be divided into 
cardiovascular and neuroendocrine ones. For example, 
cardiovascular effects include a decrease in total 
peripheral vascular resistance, drop of pulmonary 
capillary-wedge pressure, reduction in regional vascular 
resistance in the heart, kidneys, brain, and skeletal 
muscles; a reduction in systolic and diastolic volumes 
of the left ventricle; increase in stroke volume and 
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cardiac output, as well as regression of LV 
hypertrophy. Neuroendocrine effects of ACE inhibitors 
are as follows: a reduction in the formation of A-II, 
aldosterone, noradrenaline, arginine-vasopressin, and 
endothelin-1, increase in the tissues and blood content 
of bradykinin and other kinins, potassium retention, and 
the increased excretion of water, sodium, and uric acid. 
ACE inhibitors also inhibit the proliferation and 
migration of smooth muscle vascular cells, contribute 
to the stabilization of atherosclerotic patch, have 
antiplatelet action and antioxidant properties, and 
activate endogenous fibrinolysis. 
The pharmacological effects of ACE inhibitors 
are based on their ability to inhibit the activity of 
angiotensin-1-converting enzyme (or kininase II) and 
thus at the same time affect the functional activity of 
the RAAS and the kallikrein-kinin system. Inhibiting 
the activity of angiotensin-1-converting enzyme, 
ACE inhibitors reduce the formation of A-II and 
eventually weaken the major cardiovascular effects 
of RAAS including arterial vasoconstriction and 
aldosterone secretion. Inhibiting the activity of 
kininase II, ACE inhibitors reduce inactivation of 
bradykinin and other kinins and contribute to the 
accumulation of these substances in the tissues and 
blood. Kinins themselves or through the release of 
prostaglandins E2 and 12 have a vasodilatory and 
natriuretic effect. The ACE inhibitor therapy helps to 
recover an impaired endothelial function, i.e., its 
ability to release nitric oxide (endothelial relaxation 
factor) and tissue plasminogen activator. ACE 
inhibitors reduce afterload on the left ventricle of the 
heart, causing vasodilatation of systemic arteries and 
reducing the total peripheral vascular resistance, and 
thus improve its pumping function.  
ACE inhibitors can positively affect the immune 
system. For the first time in 1993, an 
immunomodulatory effect of captopril ACE inhibitor 
was shown on monocytes cells. Then, it was 
confirmed by a series of other clinical studies. For 
example, Liu found a significant decrease in the level 
of TNF-α in patients with chronic heart failure during 
therapy with four different ACE inhibitors – 
perindopril, benasepril, enalapril, and fosinopril, 
which indicates the systemic nature of anti-cytokine 
action of this class of drugs. In addition, it was noted 
that the use of high doses of enalapril ACE inhibitor 
in patients with CHF was accompanied by a 
significant reduction in levels of IL-6, and the 
thickness of the interventricular septum of the heart. 
Anticytokine effect of ACE inhibitors in patients 
with CHF is likely mediated by a reduction of 
synthesis A-II – neurohormone that increases the 
production of cytokines, including TNF-α and 
adhesive molecules through activation of the nuclear 
kappa-B factor playing an important role in the 
regulation of transcription of cytokines and adhesive 
molecules. In general, the increased levels of TNF-α, 
IL-6 and antinuclear factor are considered 
«biochemical markers» of LV insufficiency. 
According to R. Ferrari et al. an increase in the TNF 
levels is observed mainly in patients with functional 
class IV chronic heart failure.  The experimental 
animal studies revealed that ACE inhibition reduces 
some of the parameters associated with inflammation 
in the atherosclerotic lesions and controlled by 
nuclear kappa-B factor, which helps to stabilize the 
patches. High efficiency of ACE inhibitors, is most 
likely caused both by modulating neurohumoral and 
partially by anti-inflammatory effects [3]. It should 
be also noted that the literature presents the results of 
some studies on the ability of agents of standard CHF 
therapy, such as cardiac glycosides, diuretics, 
calcium antagonists and some antiarrhythmic drugs, 
in particular, amiodarone, at least partially, to reduce 
the level of cytokines.  
One also distinguishes drugs such as 
pentoxifylline and vesnarinone that increase 
intracellular cAMP levels and prevent transcription 
of TNF-α by blocking the intracellular accumulation 
of RNA and TNF-α. It should be noted that the 
positive effect of pentoxifylline is additionally 
accompanied by increased levels of inflammatory 
mediators, including IL-10, antagonists to both IL-1 
receptors and soluble TNF-α receptors. These drugs 
undergo approbation in patients with chronic heart 
failure, although some studies have produced results 
showing that vesnarinone worsens the survival ability 
of patients with CHF. It is known that glucocorticoids 
can also inhibit the synthesis of TNF-α at the 
transcriptional and translation levels [2]. Studying the 
efficacy of biological drugs specifically inhibiting the 
activity of TNF-α is of particular interest. One of 
them is Enbrel. This drug binds to a biologically 
active TNF-α and prevents its interaction with 
membrane TNF-a receptor. The drug efficacy has 
been demonstrated by the preliminary minor placebo-
controlled trials in patients with CHF. However, the 
large-scale, randomized, placebo-controlled studies 
of Etanercept, such as RENAISSANCE (Randomized 
Endrel North American Strategy to Study 
Antagonism of Cytokines) and RECOVER (Research 
into Antagonism of Cytokines), has recently been 
stopped because of the lack of positive results [13]. 
Despite the advances made in the treatment of 
patients with chronic heart failure, there is a steady 
progress of disease and a high level of mortality and 
disability. This allows suggesting that the most 
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important pathogenetic mechanisms of disease either 
retain their activity or slightly change in the course 
of treatment. These «immutable» mechanisms can 
also include both immune activation and 
inflammation. Involvement of inflammatory 
mediators in the pathogenesis of chronic heart failure 
opens new prospects for increasing the effectiveness 
of treatment of decompensated patients [18, 22, 23]. 
We should note that the immunoinflamatory concept 
of formation and progression of chronic heart failure 
remains understudied and valid.  
 
References 
1. Voloshina I.N. Dynamics of the cytokine profile 
in hypertensive patients during carvedilol treatment / 
Tauride Medical and Biological Bulletin. 2011. Vol. 14. 
No. 1 (53).  
2. Dudarenko O.P. Inhibitor of synthesis of tumor 
necrosis factor-a, pentoxifylline, in combined therapy of 
the chronic heart failure / Dudarenko O.P., Shkolnik E.L., 
Kulikov K.G., Serova M.K., Vasiuk Iu.A.// RFK. 2008. 2. 
Pp. 6-12  
3. Zhelnov V.V. ACE inhibitors in clinical practice / 
Zhelnov V.V., Petrovskaia N.V., Komarova I.S. // Russian 
Medical Journal. 2007. 15 (15). Pp. 1135-1141  
4. Kokorin V.A. Neurohumoral impairments and 
methods of their correction in patients suffering the 
myocardial infarction / Kokorin V.A., Volov N.A., 
Dudareva A.V., Sytnik N.V., Geng Haischu // Russian 
Journal of Cardiology. 2009. 1 (75) 
5.  Makkonen C.F. The content of inflammatory 
cytokines and C-reactive protein in patients with chronic 
heart failure with systolic and diastolic dysfunction of the 
left ventricle of the heart / Makkonen C.F., Suiazova S.B., 
Osipova O.A., Vlasenko M.A., Godlevskaia O.M., 
Butikova E.A., Vlasenko O.A.// Journal of Basic Research. 
Medical sciences. 2012. P. 7. 
6.  Mareev V.Iu. Diagnosis and treatment of chronic 
heart failure / Ageev F.T., Arutyunov G.P., Koroteev A.V., 
Revishvili A.Sh..// Heart failure. 2010. Vol.11. No.1: P. 57  
7. Olbinskaia L.I. The use of bisoprolol as anti-
cytokine agent / Olbinskaia L.I., Ignatenko S.B. //  
I.M. Sechenov MMU, 2004. 
8. Osipova O.A. Analysis of the importance of pro-
inflammatory cytokines in the pathogenic mechanisms of 
progression of chronic heart failure / Osipova O.A. // 
System analysis and management in biomedical systems. 
2013. Vol. 12. No. 3. Pp. 638-642.  
9. Osipova O.A. Analysis of the 
immunoinflammatory mechanisms in the development and 
progression of chronic heart failure / Osipova O.A., 
Nagibina A.I., Vlasenko M.A., Godlevskaia O.M.// System 
analysis and management in biomedical systems. 2014. 
Vol. 13. No. 1. Pp. 21-25.  
10.  Osipova O.A. Humoral mechanisms of chronic 
heart failure in patients with postinfarction  
cardiosclerosis / Osipova O.A., Vlasenko O.A.// Scientific 
journal of Belgorod State University. Series: Medicine. 
Pharmacy. 2011. Vol. 14. No.10. Pp. 77-80.  
11. Osipova O.A. Role of proinflammatory cytokines 
in the development of chronic heart failure / Osipova O.A., 
Suiazova S.B., Vlasenko M.A., Godlevskaia O.M. // 
Academician I.P. Pavlov Russian medico-biological 
bulletin. 2013. No. 2. Pp. 130-135.  
12. Osipova O.A. Cytokines in the development and 
progression of chronic heart failure / Osipova O.A., 
Vlasenko M.A., Godlevskaia O.M., Suiazova S.B. // 
Bulletin of new medical technologies. 2012. Vol. 19.  
13. No. 2. Pp. 322-327.  
14. Pribylova N.N. Neurohumoral mechanisms of 
chronic heart failure in patients with postinfarction 
cardiosclerosis / Pribylova N.N., Osipova O.A. // «Heart 
Failure» Journal. 2009. Vol. 10. No. 4. Pp. 196-198.  
15. Romanovskaia G.A. Prospects for medical 
treatment of endothelial dysfunction / Romanovskaia G.A., 
Akatova E.V., Gorokhovskaia G.N., Avetian N.G., Martyn 
A.I.// Pharmateka Journal. 2005. 9. 
16. Shilov A.M. Carvedilol in the treatment of 
cardiovascular diseases / Shilov A.M., Miller M.V. // 
Russian Medical Journal. 2007 9: Pp. 736-742.  
17. Shushliapin O.I. Effect of carvedilol on patients 
with heart failure and type 2 diabetes as polymorbidity 
pathology in internal medicine / Shushliapin O.I., Kozhin 
M.I., Dobrovolskaia I.N., Zolotaikina V.I., Titova A.Iu., 
Rynchak P.I. // Medicines of Ukraine. 2014. No. 3 (20),  
18. Anker SD, Chua TP, Swan JW. Circulation 199. 
96: 526- 34.  
19. Kolls, J. et al. Prolonged and effective blockade 
of tumor necrosis factor activity through adenovirus-
mediated gene transfer/ Proc.Natl.Acad.Sci.USA. 1994. 
91(1):215-. 9.  
20. Levine B., Kalman J., Mayer I., et al. Elevated 
circulating level of tumor necrosis factor in severe chronic 
heart failure. New Engl.J.Med. 1990. 223: 236-241.  
21. Osipova O.A. Dynamics of proinflammatory 
cytokines on the background of drug therapy in patients 
with chronic heart failure /Osipova O.A., Belousova O.N., 
Ephremova O.A., Suyazova S.B., Shabanov E.A., 
Godlevskaya O.M.// International Journal of Experimental 
Education. 2013. No. 6. P. 44-46.  
22. Osipova O.A.The level of cytokines in the blood 
of patients with st-elevation acute myocardial infarction 
Osipova O.A., Suyasova S.B., Shekhovtsova L.V., 
Nagibina A.I., Vlasenko M.A., Vlasenko O.A. 
European Journal of Natural History. 2014. № 5. Р. 31-32.  
23. Peppel K. et al. A tumor necrosis factor (TNF) 
receptor-IgG heavy chain chimeric protein as a bivalent 
antagonist of TNF activity/ J.Exp.Med.- 1991. 
174(6):1483-9.  
24.  Peppel K. et al. Expression of a TNF inhibitor in 
transgenic mice/ J.Immunol. 1993. 151(10):5699-703. 
 
 
 
